Literature DB >> 29953129

Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia.

Michael G McCusker1, Firas El Chaer1, Alison Duffy1,2, Ashkan Emadi1, Vu H Duong1.   

Abstract

Relapsed Philadelphia chromosome (Ph) positive Acute Lymphoblastic Leukemia (ALL) is an aggressive lymphoid malignancy with a poor prognosis and no randomized studies demonstrating superiority of any single salvage regimen. We present the case of a 33-year-old woman with relapsed Ph positive precursor (pre) B-cell ALL with rapidly rising peripheral blasts while on blinatumomab monotherapy initially, but ultimately responded with the addition of Vincristine Sulfate Liposome Injection (VSLI). Ponatinib was added later when it became available for the patient, and she ultimately achieved a complete remission. Further study is warranted to explore mechanisms of potential synergy, and the safety and efficacy of the combination of blinatumomab and VSLI.

Entities:  

Year:  2018        PMID: 29953129      PMCID: PMC6018018     

Source DB:  PubMed          Journal:  Am J Leuk Res


  23 in total

1.  Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.

Authors:  Sara Raponi; Maria Stefania De Propris; Stefania Intoppa; Maria Laura Milani; Antonella Vitale; Loredana Elia; Omar Perbellini; Giovanni Pizzolo; Robin Foá; Anna Guarini
Journal:  Leuk Lymphoma       Date:  2011-02-24

2.  Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

Authors:  Wendy Stock; Jeffrey L Johnson; Richard M Stone; Jonathan E Kolitz; Bayard L Powell; Meir Wetzler; Peter Westervelt; Guido Marcucci; Daniel J DeAngelo; James W Vardiman; Diane McDonnell; Krzysztof Mrózek; Clara D Bloomfield; Richard A Larson
Journal:  Cancer       Date:  2012-06-28       Impact factor: 6.860

3.  FDA Approval: Blinatumomab.

Authors:  Donna Przepiorka; Chia-Wen Ko; Albert Deisseroth; Carolyn L Yancey; Reyes Candau-Chacon; Haw-Jyh Chiu; Brenda J Gehrke; Candace Gomez-Broughton; Robert C Kane; Susan Kirshner; Nitin Mehrotra; Tiffany K Ricks; Deborah Schmiel; Pengfei Song; Ping Zhao; Qing Zhou; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

4.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Authors:  Max S Topp; Nicola Gökbuget; Gerhard Zugmaier; Petra Klappers; Matthias Stelljes; Svenja Neumann; Andreas Viardot; Reinhard Marks; Helmut Diedrich; Christoph Faul; Albrecht Reichle; Heinz-August Horst; Monika Brüggemann; Dorothea Wessiepe; Chris Holland; Shilpa Alekar; Noemi Mergen; Hermann Einsele; Dieter Hoelzer; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2014-11-10       Impact factor: 44.544

5.  Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

Authors:  Giovanni Martinelli; Nicolas Boissel; Patrice Chevallier; Oliver Ottmann; Nicola Gökbuget; Max S Topp; Adele K Fielding; Alessandro Rambaldi; Ellen K Ritchie; Cristina Papayannidis; Lulu Ren Sterling; Jonathan Benjamin; Anthony Stein
Journal:  J Clin Oncol       Date:  2017-03-29       Impact factor: 44.544

6.  Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

Authors:  Renato Bassan; Giuseppe Rossi; Enrico M Pogliani; Eros Di Bona; Emanuele Angelucci; Irene Cavattoni; Giorgio Lambertenghi-Deliliers; Francesco Mannelli; Alessandro Levis; Fabio Ciceri; Daniele Mattei; Erika Borlenghi; Elisabetta Terruzzi; Carlo Borghero; Claudio Romani; Orietta Spinelli; Manuela Tosi; Elena Oldani; Tamara Intermesoli; Alessandro Rambaldi
Journal:  J Clin Oncol       Date:  2010-07-06       Impact factor: 44.544

7.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial.

Authors:  Josep-Maria Ribera; Albert Oriol; Marcos González; Belén Vidriales; Salut Brunet; Jordi Esteve; Eloy Del Potro; Concepción Rivas; Maria-José Moreno; Mar Tormo; Victoria Martín-Reina; Josep Sarrá; Ricardo Parody; Jaime Pérez de Oteyza; Encarna Bureo; Maria-Teresa Bernal
Journal:  Haematologica       Date:  2009-10-01       Impact factor: 9.941

Review 8.  Blinatumomab: a historical perspective.

Authors:  Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Journal:  Pharmacol Ther       Date:  2012-08-24       Impact factor: 12.310

9.  A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.

Authors:  J E Cortes; D-W Kim; J Pinilla-Ibarz; P le Coutre; R Paquette; C Chuah; F E Nicolini; J F Apperley; H J Khoury; M Talpaz; J DiPersio; D J DeAngelo; E Abruzzese; D Rea; M Baccarani; M C Müller; C Gambacorti-Passerini; S Wong; S Lustgarten; V M Rivera; T Clackson; C D Turner; F G Haluska; F Guilhot; M W Deininger; A Hochhaus; T Hughes; J M Goldman; N P Shah; H Kantarjian
Journal:  N Engl J Med       Date:  2013-11-01       Impact factor: 91.245

10.  UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.